Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

April 22, 2024

Study Completion Date

April 22, 2024

Conditions
Enterobacteriaceae Infections
Interventions
DRUG

Piperacillin-tazobactam

"At the time of ventilator-associated pneumonia diagnosis, patients will receive an initial 4g loading dose of piperacillin-tazobactam with a continuous maintenance dose of 16g per day the first day of treatment. The dose of the piperacillin-tazobactam administered the following days will be adjusted to the renal function.~The antimicrobial treatment will be adjusted to the narrower-spectrum agent after the antimicrobial susceptibility determination for a total length of treatment of seven days."

Trial Locations (2)

33000

Hopital Pellegrin, Bordeaux

64100

Centre hospitalier de la Côte Basque, Bayonne

All Listed Sponsors
lead

University Hospital, Bordeaux

OTHER